General Information of Drug (ID: DM82C6Q)

Drug Name
Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-) Drug Info
Synonyms
Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-); Fc-131; FC131; CHEMBL436283; FC 131; 606968-52-9; CHEMBL2180076; AC1NQNK6; SCHEMBL15987252; ZINC3925712; Cyclo(-Nal-Gly-D-Tyr-Arg-Arg-); BDBM50399002; BDBM50166106; KB-272560; B7647; N-{3-[(2S,5S,8S,14R)-5-(3-Guanidino-propyl)-14-(4-hydroxy-benzyl)-8-naphthalen-2-ylmethyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-propyl}-guanidine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5275843
TTD Drug ID
DM82C6Q

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Plerixafor DMCJN1P Non-hodgkin lymphoma 2B33.5 Approved [2]
Motixafortide DMW34B1 Multiple myeloma 2A83 Approved [3]
Ulocuplumab DM6PMNR Multiple myeloma 2A83 Phase 3 [4]
Balixafortide DMUOFAC Metastatic breast cancer 2C6Y Phase 3 [5]
AMD-070 DMVOY6B Whim syndrome 4A00.Y Phase 3 [6]
TG-0054 DM2ZLWH Macular degeneration 9B78.3 Phase 2 [7]
POL-6326 DM4OT29 Human immunodeficiency virus infection 1C62 Phase 2 [8]
CTCE-9908 DM95XR8 Sarcoma 2A60-2C35 Phase 1/2 [9]
USL311 DM6HPEC Recurring respiratory infection CA07-CA45 Phase 1/2 [10]
GMI-1359 DML1KSA Breast cancer 2C60-2C65 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-X-C chemokine receptor type 4 (CXCR4) TTBID49 CXCR4_HUMAN Inhibitor [1]

References

1 Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4124-9.
2 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
3 The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. November 15, 2013; Blood: 122 (21).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
6 Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):559-65.
7 CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015;24(7):1313-28.
8 CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):251-64.
9 A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug;155(2):231-6.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Clinical pipeline report, company report or official report of GlycoMimetics.